SCHADE CHRISTIAN S 4

4 · Aprea Therapeutics, Inc. · Filed Mar 1, 2021

Form 4

Period: 2021-02-25

DirectorPresident & CEO

Transactions

Award
Stock Option (right to Buy)
2021-02-25+329,000→ 329,000 total
Exercise: $6.00Exp: 2031-02-25→ Common Stock (329,000 underlying)
Award
Common Stock
2021-02-25+88,500→ 176,660 total
Award
Common Stock
2021-02-25+77,000→ 77,160 total

Holdings

Footnotes (4)

[F1]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,666 shares on February 25, 2022, (ii) 25,667 shares on February 25, 2023 and (iii) 25,667 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
[F2]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 29,500 shares on August 25, 2021, (ii) 29,500 shares on February 25, 2022 and (iii) 29,500 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
[F3]Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
[F4]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

Documents

1 file